ArticleCancer chemotherapy and pharmacology2023

Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.

Emmanuelle Jacquet et al.PubMed ↗Publisher ↗

No numbers read from the abstract.